PT - JOURNAL ARTICLE AU - Kirwan, Peter D AU - Foulkes, Sarah AU - Munro, Katie AU - Sparkes, Dominic AU - Singh, Jasleen AU - Henry, Amanda AU - Dunne, Angela AU - Timeyin, Jean AU - Russell, Sophie AU - Khawam, Jameel AU - Blick, Debbie AU - Otter, Ashley D AU - Hettiarachchi, Nipunadi AU - Cairns, Michelle D AU - Jackson, Christopher H AU - Seaman, Shaun AU - Brown, Colin S AU - SIREN Study Group AU - Atti, Ana AU - Islam, Jasmin AU - Charlett, Andre AU - De Angelis, Daniela AU - Presanis, Anne M AU - Hall, Victoria J AU - Hopkins, Susan TI - Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024 AID - 10.1101/2024.09.11.24313477 DP - 2024 Jan 01 TA - medRxiv PG - 2024.09.11.24313477 4099 - http://medrxiv.org/content/early/2024/09/12/2024.09.11.24313477.short 4100 - http://medrxiv.org/content/early/2024/09/12/2024.09.11.24313477.full AB - Objective To estimate the protection of COVID-19 vaccine boosters against mild/asymptomatic and moderate SARS-CoV-2 infection over a 6-month period of XBB.1.5 and JN.1 variant circulation.Design Multi-state model applied to cohort study, adjusted for vaccination, prior infection, and demographic covariates.Setting National Health Services (NHS) hospitals in the UK.Participants Healthcare worker cohort including 2,867 eligible people with >6 months since a previous booster who tested fortnightly for SARS-CoV-2 between October 2023 and March 2024 and completed symptoms questionnaires.Main outcome measures Vaccine effectiveness (VE) of vaccine boosters received in October 2023 (baseline: booster >6 months prior), and durability of protection from a recent (past 6 months) previous infection (baseline: last infection >2 years prior) against mild/asymptomatic and moderate SARS-CoV-2 infection. Mild symptoms included acute respiratory symptoms for <5 days, moderate symptoms included influenza-like illness, acute respiratory symptoms for 5+ days, or sick-leave. VE and acquired protection were estimated from the multi-state model as: 1 – adjusted hazard ratio.Interventions Receipt of a COVID-19 bivalent original/BA.4-5 or monovalent XBB.1.5 booster during October 2023.Results Half of eligible participants (1,422) received a booster during October 2023 (280 bivalent, 1,142 monovalent) and 536 (19%) had at least one PCR-confirmed infection over the study period. For the monovalent booster, VE against infection was 44.2% (95% confidence interval 21.7 to 60.3%) at 0-2 months, and 24.1% (-0.7 to 42.9%) at 2-4 months post-vaccination, with no evidence of protection by 4-6 months. For the bivalent booster, VE against infection was 15.1% (-55.4 to 53.6%) at 0-2 months and 4.2% (-46.4 to 37.3%) at 2-4 months. VE (monovalent or bivalent) against moderate infection was 39.7% (19.9 to 54.6%), and against mild/asymptomatic infection was 14.0% (-12.1 to 34.0%). Controlling for vaccination, compared to those with an infection >2 years prior, infection within the past 6 months was associated with 58.6% (30.3 to 75.4%) increased protection against moderate infection, and 38.5% (5.8 to 59.8%) increased protection against mild/asymptomatic infection.Conclusions Monovalent XBB.1.5 boosters provided short-term protection against SARS-CoV-2 infection, particularly against moderate symptoms. Vaccine formulations which target the circulating variant may be suitable for inclusion in seasonal vaccination campaigns among healthcare workers.Funding UK Health Security Agency, Medical Research Council, NIHR HPRU Oxford, and others.Competing Interest StatementCSB and SH report grant funding from the NIHR HPRU; CSB reports participation in an ad-hoc one-off market research advisory on a variety of infection topics; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.Clinical Protocols https://doi.org/10.1186/ISRCTN11041050 Funding StatementThis work was supported by the UK Health Security Agency, the UK Department of Health and Social Care, with contributions from the governments of Northern Ireland, Scotland and Wales, the National Institute for Health Research (NIHR), the UK Medical Research Council (Unit Programme Number MC_UU_00002/11 (PDK, CHJ, AMP, DDA), and MC_UU_00040/05 (SS)), UK Research and Innovation (UKRI Grant Ref MR/W02067X/1 (SH, VH)), NIHR Health Protection Research Unit (HPRU) Oxford (SH), NIHR HPRU in Behavioural Science and Evaluation at University of Bristol, in partnership with UKHSA (PDK, AMP, DDA, AC), and others.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Berkshire Research Ethics Committee of the NHS Health Research Authority gave ethical approval for this work (IRAS ID 284460, REC reference 20/SC/0230).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe anonymised SIREN dataset will be made available for secondary analysis to approved researchers upon reasonable request, subject to appropriate information governance requirements.